Newsome, Scott D. http://orcid.org/0000-0002-5284-4681
Binns, Cherie http://orcid.org/0009-0007-2113-9836
Kaunzner, Ulrike W. http://orcid.org/0000-0001-9449-7369
Morgan, Seth
Halper, June http://orcid.org/0000-0003-0632-7074
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Received: 19 May 2023
Accepted: 19 September 2023
First Online: 11 October 2023
Declarations
:
: Scott D. Newsome has received consulting fees for scientific advisory boards from Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Greenwich Biosciences, Horizon Therapeutics, Novartis, and TG Therapeutics; is an advisor for Autobahn; is the study lead principal investigator for a Roche clinical trial; and has received research funding (paid directly to institution) from Biogen, Department of Defense, Genentech, National Multiple Sclerosis Society, Patient-Centered Outcomes Institute, Roche, and Stiff Person Syndrome Research Foundation. Cherie Binns has received consulting fees from Novartis for manuscript development and advisory panels. Ulrike W. Kaunzner has participated in advisory boards for Genentech and Novartis. Seth Morgan has nothing to disclose. June Halper serves as a paid consultant to MS-LINK (an EMD Serono project); is a volunteer journal club speaker; and has received consulting fees from Novartis for manuscript development.
: This article does not contain any new studies with human participants or animals performed by any of the authors.